Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with increased oxidative stress. In this context, pharmacological activation of the Keap1-Nrf2 pathway, a key regulator of ...

C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million.

LOS ANGELES, CA, UNITED STATES, January 27, 2026 /EINPresswire.com/ — Osato Research Institute today announced that Immun’Âge ®, a fermented papaya preparation ...

Ra Pharmaceuticals Inc (NASDAQ:RARX) announced an agreement to be acquired by Belgian biopharma UCB for $48 per share in cash or $2.5 billion in total. The boards of both companies approved the ...